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Abstract
Background: The 'Hawthorne Effect' may be an important factor affecting the generalisability of
clinical research to routine practice, but has been little studied. Hawthorne Effects have been
reported in previous clinical trials in dementia but to our knowledge, no attempt has been made
to quantify them. Our aim was to compare minimal follow-up to intensive follow-up in participants
in a placebo controlled trial of Ginkgo biloba for treating mild-moderate dementia.
Methods:  Participants in a dementia trial were randomised to intensive follow-up (with
comprehensive assessment visits at baseline and two, four and six months post randomisation) or
minimal follow-up (with an abbreviated assessment at baseline and a full assessment at six months).
Our primary outcomes were cognitive functioning (ADAS-Cog) and participant and carer-rated
quality of life (QOL-AD).
Results: We recruited 176 participants, mainly through general practices. The main analysis was
based on Intention to treat (ITT), with available data. In the ANCOVA model with baseline score
as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-
Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the
intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference
= -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group). There was no
significant difference on carer quality of life.
Conclusion: We found that more intensive follow-up of individuals in a placebo-controlled clinical
trial of Ginkgo biloba for treating mild-moderate dementia resulted in a better outcome than
minimal follow-up, as measured by their cognitive functioning.
Trial registration: Current controlled trials: ISRCTN45577048
Background
The so-called 'Hawthorne Effect' may be an important fac-
tor affecting the generalisability of clinical research to rou-
tine practice, but has been little studied. Consider the
following scenario: a clinician assesses a patient with
Alzheimer's disease, decides to prescribe a treatment to
improve cognition and reassesses the patient six months
later. At follow-up, the patient appears marginally worse,
so, the clinician, mindful of the fact that in published
dementia trials, people receiving active medication often
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appear better or stable stops the drug, believing this to be
a treatment failure. But the clinician has not taken into
account the possible impact of the Hawthorne Effect on
the trial results that guide his practice- patients in clinical
trials appear to fare better than those in routine practice by
virtue of their participation. He may have stopped his
patient's medication unnecessarily.
The Hawthorne Effect was first reported following an
extensive research programme investigating methods of
increasing productivity in the Western Electrical Com-
pany's Hawthorne Works in Chicago during the 1920s
and 30s [1,2]. The finding of enduring interest was that no
matter what change was introduced to working condi-
tions, the result was increased productivity. For example,
improving or reducing the lighting in the production
areas under test produced similar effects. It has been
defined as 'an increase in worker productivity produced
by the psychological stimulus of being singled out and
made to feel important' [3]. Subsequently the definition
has been broadened; here it refers to treatment response
rather than productivity.
Although first reported in industrial research, the Haw-
thorne Effect clearly may have its implications for clinical
research and its generalisability to routine practice. If
there is a demonstrable benefit from participating in clin-
ical research, for whatever reason, then this has implica-
tions for good clinical practice and for improving care
[4,5]. The Hawthorne Effect is a component of the non-
specific effects of trial participation, but is not controlled
for by usual controlled trial designs.
Most clinical trials are unable to quantify the magnitude
of the Hawthorne Effect because its defining features, such
as extra attention by researchers and higher levels of clin-
ical surveillance, apply equally to treatment and control
arms. Although the Hawthorne Effect should not affect
assessment of the difference between intervention and
control, it may result in an inflated estimate of effect size
in routine clinical settings by over-estimating response in
both groups.
Hawthorne Effects have been suggested in previous clini-
cal trials in dementia but as far as we are able to deter-
mine, no attempt has been made to quantify them. To
quantify the magnitude of the Hawthorne Effect, in the
context of a placebo-controlled study of an intervention
for treating mild-moderate dementia, we compared inten-
sive to minimal follow-up in a randomised fashion. Our
aim was to determine whether intensive follow-up had an
effect on cognition, quality of life, behavioural function-
ing and/or psychopathology, as compared to minimal fol-
low-up.
Our primary null hypothesis for this component of the
trial was that compared to minimal follow-up, intensive
follow-up would have no additional effect on partici-
pants' in a placebo controlled trial of Ginkgo biloba for
treating mild-moderate dementia in a community setting,
as measured by the ADAS-Cog (the Alzheimer's Disease
Assessment Scale – Cognitive subscale) [6] and the partic-
ipant's quality of life, as measured by the QOL-AD (Qual-
ity of Life in Alzheimer's Disease assessment scale) [7].
Methods
We conducted a 2 × 2 factorial, community-based, prag-
matic, randomised, double-blind, parallel-group trial in
which participants were treated, double-blind with an
high-purity extract of Ginkgo biloba (120 mg daily) or
placebo for six months (the DIGGER trial: Dementia In
General Practice Ginkgo Extract Research). In addition to
randomisation to treatment, participants were ran-
domised to intensive or minimal follow-up (see below for
details). The factorial design was economical in terms of
the numbers of patients required to address the two ques-
tions. The trial was approved by South West Multi-Centre
Research Ethics Committee (ref:MREC/02/6/35) and was
registered with Current Controlled Tri-
als(ISRCTN45577048). The trial was sponsored by Lon-
don West Mental Health Research and Development
Consortium, and funded by the Alzheimer's Society.
There was extensive consumer involvement, through the
Alzheimer's Society, at all stages.
Participants
We recruited participants in Greater London (UK) and
adjacent regions through referrals from general practition-
ers, old age psychiatrists and other health care profession-
als; and from direct responses to advertising in Alzheimer
Society newsletters, London-based newspapers, and post-
ers in Age Concern centres.
Eligibility was determined with reference to the following:
Inclusion criteria
￿ Aged 55 years or over
￿ Presence of a carer able to report on the functioning of
the participant
￿ Informed consent of the participant or in the case of an
individual who lacks the capacity to give their consent,
their assent and the agreement of their nominated carer
￿ Sufficient command of English to complete question-
naires
￿ Clinical diagnosis of dementia (sub-classified using
DSM-IV criteria) [8]BMC Medical Research Methodology 2007, 7:30 http://www.biomedcentral.com/1471-2288/7/30
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￿ A Mini Mental State Examination (MMSE) [9] score of
12–26 inclusive
￿ Living in the community
Exclusion criteria
￿ Use of Ginkgo in two weeks prior to the baseline assess-
ment
￿ Commencement of cholinesterase inhibiting drugs
within 2 months of baseline or during follow-up
￿ Concomitant warfarin therapy
￿ Known bleeding abnormalities
Interventions (follow-up)
In order to assess the Hawthorne Effect, participants were
randomised to intensive follow-up (with comprehensive
assessment visits at baseline and two, four and six months
post randomisation) or minimal follow-up (with an
abbreviated assessment at baseline and a full assessment
at six months). To minimise the chances that any differ-
ence was due to medication intake, the minimal follow-
up group was sent their study medication by post (Royal
Mail) at two-monthly intervals. All visits were domicili-
ary.
Outcomes
Our primary outcome measures were: i) cognitive func-
tioning, as measured by the ADAS-Cog, a 0–70 point scale
with a higher score indicating worse cognition; and ii)
quality of life, rated by the participant and their nomi-
nated carer, as measured by the QOL-AD, both 13-item
scales, scoring between 13 and 52 points with a higher
score indicating better quality of life. Both outcome meas-
ures are validated tools previously (and in most cases
commonly) used in dementia trials. Other measures
undertaken at each assessment as part of the therapy com-
ponent of the trial included a measure of psychopathol-
ogy, a social behaviour scale, a caregiver burden scale and
a blood test for coagulation time. We decided, a priori, not
to consider these outcomes in the Hawthorne analysis.
Each patient and caregiver assessment took approximately
1.5 to 2 hours. All outcomes were administered by a
trained researcher during a home visit. The ADAS-Cog was
scored by the researcher; all other measures were scored
by the participant or their carer.
Sample size
As we knew of no studies that had attempted such a com-
parison before, we did not power the study to detect a dif-
ference between the follow-up groups. Instead we relied
on the sample size calculation for effect of Ginkgo over
placebo, which gave a target sample size of 200 partici-
pants. This sample size was sufficient to detect a 4-point
between-group difference in ADAS-cog with 80% power
at 5% significance.
Randomisation procedure and blinding
A 2 × 2 factorial design involving two separate randomisa-
tions, resulting in participants being randomised to one of
four arms, was employed. Both factors consisted of two
levels: medication group (Ginkgo and placebo); and level
of follow-up (minimal or intensive). This produced four
groups: the Ginkgo group with intensive follow-up, the
Ginkgo group with minimal follow-up, the placebo group
with intensive follow-up and the placebo group with min-
imal follow-up. The randomisation codes were generated
usingthe computer algorithm RCODE v.4.8 (Schwabe,
2002).
The Ginkgo vs. placebo component of the trial was dou-
ble-blind, but it was not possible to blind the Hawthorne
component of the trial as both researchers and partici-
pants needed to know when the next assessment would
be.
Statistical methods
The primary analysis was intention to treat (ITT) with
available data, by randomisation group. We were inter-
ested in the effects of intensity of follow-up; participants
who withdrew from the study were not exposed to the
"intervention", so analysis with imputed data was not
thought appropriate.
In order to take account of the baseline score, when com-
paring the outcomes between the treatment groups, anal-
ysis of co-variance (ANCOVA) was used. Normal
distributions were assumed for the ANCOVA analyses and
were checked using residuals from the regression models.
If data showed substantial deviations from these assump-
tions, appropriate transformations were applied. Adjusted
differences in means (β) are presented with 95% confi-
dence intervals and p values. Chi-square test was used for
comparison of proportions. The analysis was conducted
using SPSS v.13 (SPSS Corporation, 2004) and
STATAv.8.1 (STATA Corporation, 2003).
Results
Figure 1 details participant flow through the trial for the
Hawthorne analysis. Recruitment took place between Feb-
ruary 2003 and June 2005. Table 1 presents baseline
demographic and clinical characteristics of the partici-
pants and baseline demographic characteristics of their
carers. 119 GP practices, representing 388 individual GPs,
recruited for the trial. Of the 176 participants in the trial,
132 (75%) were recruited through their GP.BMC Medical Research Methodology 2007, 7:30 http://www.biomedcentral.com/1471-2288/7/30
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At baseline and prior to randomisation, participants and
their carers were asked which follow-up group they would
prefer, and told that their preference would not affect the
group to which they were assigned (Table 2). There was no
interaction between the two randomisation factors (inten-
sity of follow-up and treatment group).
Data on effectiveness of Ginkgo versus placebo, and
adverse events will be reported elsewhere. To summarise
these findings however, in the ANCOVA model with base-
line score as a co-variate (n = 176), we found no evidence
that a standard dose of high purity Ginkgo biloba confers
benefit over placebo in mild-moderate dementia over six
months.
Main analysis
The main analysis for this paper was based on Intention
to treat (ITT), with available data. In the ANCOVA model
with baseline score as a co-variate, follow-up group had a
significant effect on outcome at six months on the ADAS-
Cog score (n = 140; β = 2.018; 95%CI -3.914, -0.121; p =
0.037), favouring the intensive follow-up group. There
was also a significant effect on participant-rated quality of
life score (n = 142; β = -1.382; 95%CI -2.642, -0.122; p =
0.032) favouring the minimal follow-up group. There was
no significant effect of follow-up group on carer-rated
quality of life score (n = 131; β = 0.169; 95%CI -1.489,
1.827; p = 0.841).
Per protocol analysis
This included individuals who were followed-up at all
allocated time-points; who provided data at baseline and
six months; and who did not withdraw. In the ANCOVA
model with baseline score as a co-variate, follow-up group
had a significant effect on outcome at six months on the
ADAS-Cog score (n = 116; β = -2.376; 95%CI -4.519, -
0.233; p = 0.030), which favoured the intensive follow-up
group. Follow-up group did not have a significant effect
on neither participant-rated quality of life score (n = 115;
β = -1.238; 95%CI -2.683, 0.207; p = 0.092) or carer-rated
quality of life score (n = 106; β = 0.317; 95%CI -1.359,
1.994; p = 0.708).
Participant flowchart Figure 1
Participant flowchart.
Randomised
(n=176)
Assessed for eligibility
(n=646)
Excluded (n=470) 
Age (n=5)
Bleeding abnormalities (n=2) 
Blood coagulation times (n=3)
Concomitant illness (n=22) 
Couldn’t arrange assessment 
during recruitment (n=6) 
Current Warfarin therapy (n=15)
English language ability (n=3)
Continued Ginkgo use (n=13) 
MMSE score <12 (n=20)
MMSE score >26 (n=79)
No carer (n=15)
Non-consent of carer (n=112) 
Non-consent of GP (n=1) 
Non-consent of potential 
participant (n=151) 
Outside catchment area (n=1) 
Potential participant died before 
interview (n=11) 
Uncontactable (n=11) 
Allocated to minimal follow-up (n=88)
Received allocated intervention (n=88)
Followed up per protocol (n=68)
Allocated to intensive follow-up (n=88)
Received allocated intervention (n=88)
Followed up per protocol (n = 70)
Withdrew (n=20)* 
Adverse event (n=3)
Blood coagulation time outside normal range 
(n=4) 
Non-consent (n=7) 
Started AChI (n=1) 
Concomitant disease (n=3) 
Lost to follow-up (n=1) 
Participant died (n=1)
Withdrew (n=25)* 
Adverse event (n=4)
Blood coagulation time outside normal range 
(n=3) 
Non-consent (n=5) 
Concomitant disease (n=4) 
Lost to follow-up (n=1) 
Participant died (n=3)
‘Treatment ineffective’ (n=5) 
Follow-up 
Allocation 
Analysed (n=71)  Analysed (n=69)  ITT analysis
* note: some patients who were withdrawn due to adverse events or coagulation anomalies had follow-up data available and 
were included in analysis BMC Medical Research Methodology 2007, 7:30 http://www.biomedcentral.com/1471-2288/7/30
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The main analysis is based on evaluable data with 71 par-
ticipants in the minimal follow-up group and 69 in the
intensive follow-up group. Twelve participants (13.7%) in
the minimal followup group and 26 (29.5%) in the inten-
sive follow-up group were not followed-up according to
protocol (i.e. two or four visits respectively in the six
months). This difference is statistically significant (χ =
6.578; d.f. = 1; p = 0.010). The rate of withdrawal was sim-
ilar between groups (22 in the minimal group and 23 in
the intensive group) as was compliance with trial medica-
tion (taking 80% or more of the allocation – 72 in the
minimal follow-up group and 69 in the intensive follow-
up group). Neither of these differences is significant.
There was no significant difference in the number of GP
contacts during the study between intensive (16 contacts)
and minimal groups (16 contacts) evaluated by self-report
at 6 months.
Discussion
We found that more intensive follow-up of individuals in
a placebo-controlled clinical trial of Ginkgo biloba for
treating mild-moderate dementia resulted in a better out-
come than minimal follow-up, as measured by their cog-
nitive functioning. Participants in our study had a
maximum of four assessment points at 2 monthly inter-
vals: less intensive than some other trials. For example
participants in two trials of donepezil had 7 assessments
in 14 weeks and 26 weeks respectively [10,11], Such
assessment protocols may result in a greater Hawthorne
Effect. This is the first example of a randomised controlled
investigation of trial effects where both groups have com-
parable (baseline) characteristics. Our findings accord
with previous literature [4,5] – which suggest that there
may be a small, positive effect of trial participation on
response – and our results suggests that the intensity of
follow-up could be a factor here.
The mean difference between the follow-up groups was
two points on the ADAS-Cog. This may not be regarded as
particularly clinically significant, but is of similar magni-
tude to that reported in randomised controlled trials of
cholinesterase inhibitors for dementia [12].
Table 1: Baseline demographic and clinical characteristics of participants and demographic characteristics of carers, by follow-up 
group
PARTICIPANTS
Characteristic Minimal group
(n = 88)
Intensive group
(n = 88)
Total sample
(n = 176)
Mean age* 79.2 (6.8) 79.7 (8.4) 79.5 (7.6)
Females, Males†† 55, 33 (62.5%) 52, 36 (59.1%) 107, 69 (60.8%)
Ethnicity†† White: 83 (94.3%)
Mixed: 1 (1.1%)
Indian: 2 (2.3%)
Black: 2 (2.3%)
White: 84 (95.5%)
Indian: 1 (1.1%)
Black: 3 (3.4%)
White: 167 (94.9%)
Mixed: 1 (0.6%)
Asian or Asian British: 3 (1.7%)
Black or Black British: 3 (3.4%)
Median years of education† 10.0 (9.0, 14.0) 10.0 (9.0, 13.1) 10.0 (9.0, 13.3)
Number with Alzheimer's disease, vascular dementia diagnosis†† 71, 17 (80.7%) 77, 11 (87.5%) 148, 28 (84.1%)
Evidence of vascular pathology†† 40 (45.5%) 46 (52.3%) 86 (48.9%)
Median MMSE score† 22.0 (15.0, 26.0) 23.0 (13.9, 26.0) 22.0 (15.0, 26.0)
Mean ADAS-Cog score* 23.2 (10.2) 22.3 (8.9) 22.7 (9.6)
Median carer-reported duration of dementia in years† 3.0 (1.0, 8.1) 3.0 (1.3, 8.0) 3.0 (1.0, 8.0)
AChI use†† 28 (31.8%) 30 (34.1%) 58 (33.0%)
CARERS§
Characteristic Minimal group
(n = 88)
Intensive group
(n = 88)
Total sample
(n = 176)
Mean age* 63.1 (14.4) 65.2 (12.9) 64.1 (13.7)
Females, Males†† 77, 11 (87.5%) 75, 13 (85.2%) 152, 24 (86.4%)
Number who are the partner of the participant†† 45 (51.1%) 48 (54.5%) 93 (52.8%)
Number who live-in†† 56 (63.6%) 59 (67.0%) 115 (65.3%)
Number who are the informal (unpaid) carer†† 83 (94.3%) 86 (97.7%) 169 (96.0%)
* Mean scores are reported with standard deviations.
† Median scores are reported with 10th & 90th percentiles.
†† Numbers reported with percentage of group (e.g. Ginkgo group); or percentage of females or AD sufferers respectively.
§ Two participants study carers changed during follow-up. Data is presented for the carer at the end of follow-up.BMC Medical Research Methodology 2007, 7:30 http://www.biomedcentral.com/1471-2288/7/30
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We also found a significant difference in participant-rated
quality of life score in the main analysis, suggesting qual-
ity of life was worse in participants who were intensively
followed-up. This may seem to be contrary to the impact
on cognition, as improved quality of life may be expected
to mirror better cognition scores. However, improved
ADAS-cog scores in this study may not reflect better cog-
nition (participation is a study per se is unlikely to
improve cognitive performance), but be due to Haw-
thorne or learning effects. Evidence of a possible Haw-
thorne effect may be supported by the finding that more
intensive contact leads to lower reported quality of life.
Previous literature [13] suggests that more intensive con-
tact may lead to a better recognition of needs. This may in
part be due to more 'honest' reporting of needs if inten-
sively followed-up as there is a better relationship with the
care provider. A similar honesty premium may have oper-
ated in the intensively followed up group here. Another
possibility is that more intensive contact with study per-
sonnel led to greater awareness of the diagnosis and
resultant disability, impairing perception of quality of life.
This explanation may account for the lack of differences in
carer QOL.
Some researchers have criticised the interpretation of the
original research about the Hawthorne Effect [14]. Other
possible variables which may have contributed to the
observed effect include managerial input; the fear of los-
ing one's job during The Great Depression; the duration of
rest breaks; and the changing of participants and human
relations, among many factors contributing to the overall
lack of scientific rigour. Indeed the first statistical analysis
of the findings found most of the variation was explained
by other factors [3]; other researchers argue that the effect
was minimal at best [15,16]; and yet others have not man-
aged to replicate the findings [17]. As a result the useful-
ness of the term has been questioned; as it is effectively a
catch-all term for labelling psychological and social fac-
tors that weren't controlled for or that cannot be
explained. Parsons [18] defined it as 'the confounding
that occurs if experimenters fail to realize how the conse-
quences of subjects' performance affect what subjects do".
Nevertheless and perhaps erroneously, the term 'Haw-
thorne Effect', coined by French [19] many years after the
original experiments, has come to be understood as, the
effect on outcome through the participation in research.
There are limitations to our study. We have looked at a
specific group: individuals with mild-moderate dementia
in a community setting, and the effect may be limited to
this group especially as learning, and/or habituation to
the assessment process over time, may be significant com-
ponents of improved outcome in dementia trials. A Haw-
thorne Effect has been previously suggested in dementia
trials [20,21], which drove our investigation. It has been
suggested [20,21] that an observed effect amongst such a
group may be due to a learning effect whereby familiarity
with the instruments results in better performance. To
minimise learning effects, we used different word lists for
the memory items (sections one and seven of the ADAS-
Cog) at each follow-up point. These items account for the
majority of variation in ADAS-Cog scores amongst indi-
viduals with mild-moderate dementia [22]. Furthermore,
the overall test-retest coefficient was found to be 0.91 over
a six week period [23], which does not suggest there is a
significant learning effect associated with the ADASCog.
The opposite argument can also be made: people with
dementia have a reduced ability to learn and learning
effects may thus be smaller in this group than others. Our
results do not allow us to rule out either possibility, and if
this is the case, the Hawthorne effect may be larger in non-
dementia trials.
Another limitation is the lack of blinding of participants
and researchers to follow-up group. This may have a
'nocebo effect' in that those minimally followed-up may
feel that they are not getting the 'best care' during their
participation. However as Table 2 shows, two-thirds of the
participants and over half of the carers expressed no pref-
erence in respect of follow-up frequency. Furthermore, the
distribution of preference was similar between the groups
(i.e. half of those participants who preferred minimal fol-
low-up received minimal follow-up). This suggests that
such an effect may not be of great import. A further possi-
ble limitation is that we assessed participants in their own
home, rather than in hospital as most studies do, and this
may have reduced the impact of trial participation.
The situation around adherence to protocol is complex.
There is an imbalance in the follow-up rates between the
groups: intensive follow up patients were less likely to be
Table 2: Participant and carer follow-up group preference, as 
stated prior to randomisation*
Participants
Minimal 
group
(n = 88)
Intensive 
group
(n = 88)
Total sample
(n = 176)
Prefer minimal 10 (5.8%) 9 (5.3%) 19 (11.1%)
Prefer intensive 17 (9.9%) 19 (11.1%) 36 (21.1%)
No preference 59 (34.5%) 57 (33.3%) 116 (67.8%)
Missing 2 (0.02%) 3 (0.03%) 5 (0.06%)
Carers
Prefer minimal 9 (5.1%) 9 (5.1%) 18 (10.2%)
Prefer intensive 35 (19.9%) 30 (17.0%) 65 (36.9%)
No preference 44 (25.0%) 49 (27.8%) 93 (52.8%)
* Percentages given are of total number of participants or total 
number of carers respectively.BMC Medical Research Methodology 2007, 7:30 http://www.biomedcentral.com/1471-2288/7/30
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followed up according to the protocol. This may be due to
the greater demands on participants and their carers in
this group. This may introduce bias, with more compliant
participants remaining in the study. However the main
analysis is based on evaluable data, with similar numbers
in the groups providing data at six months (71 in the min-
imal, 69 in the intensive). The imbalance in numbers fol-
lowed-up according to protocol is due to missed two or
four month assessments in the intensive follow-up group,
making their assessment schedule more similar to that of
the minimal follow up group. This reduces the difference
between groups and is likely to underestimate the effect.
Rates of attrition and compliance to the trial medication
did not differ significantly between groups.
It is possible that there is a threshold effect: any participa-
tion in a clinical trial is associated with a different out-
come from that of routine care, but the difference between
levels of follow up within a clinical trial is small. This is
perhaps the most relevant question in terms of generalis-
ability of clinical trial findings to routine practice, but we
did not attempt to answer it, and a different methodology
would have been required to do so.
We draw two main implications from our findings. The
first relates to how treatment effects may be over-esti-
mated as a result of follow-up in trials. If there is an une-
ven rate of drop-out between groups, the benefit to the
group with less attrition may be inflated because of the
added effect of follow-up. In dementia research, more
people tend to drop-out of the treatment arm; this would
lead to an underestimate of the effect size of the interven-
tion. Secondly it may have implications for best practice
because if trial participation improves outcome (for what-
ever reason), it can be argued that routine treatment
should be carried out under similar conditions to clinical
trials [5]. This, of course, may have resource implications
and the issue might be best considered in the context of
maximising the non-specific effects of treatment. If our
findings are replicated, the presence of a Hawthorne Effect
should be considered when interpreting the results of
treatment trials in dementia.
Hrobjartsson and Gotzsche [24] in a systematic review of
placebo effects found placebo had minimal clinical effect
compared to usual treatment. Braunholtz et al [4] system-
atically reviewed whether participation in clinical trials is
beneficial or otherwise to patients, they defined separately
treatment, protocol, care, Hawthorne and placebo effects,
but remarked that it is difficult to tease such effects apart.
The conclusion was that there is weak and inconclusive
evidence of benefit of a Hawthorne Effect. A 'structured'
review [5] compared outcomes in cancer patients treated
within and outside clinical trials and found little evidence
in support of a beneficial trial effect. Both these reviews
focussed on cancer and both groups of authors agreed on
the paucity of good quality evidence, considering the rea-
son for this to be the methodological difficulties inherent
in trying to make such evaluations in an ethical manner,
with full and informed consent while maintaining com-
parable trial and non-trial groups.
Conclusion
In a randomised, non-blind comparison of intensive and
minimal follow up of community dwelling patients suf-
fering from mild-to-moderate dementia, we found evi-
dence of a small 'Hawthorne Effect'. This may be due to
effects other than being observed, such as learning effects
of repeated exposure to the ADAS cog or greater familiar-
ity with the research process. In any event, a non-treat-
ment driven effect remains intriguing and clinically
relevant, whatever the cause.
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